377 related articles for article (PubMed ID: 32051265)
21. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.
Schleiss MR; Choi KY; Anderson J; Mash JG; Wettendorff M; Mossman S; Van Damme M
Vaccine; 2014 May; 32(23):2756-62. PubMed ID: 23867012
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
[TBL] [Abstract][Full Text] [Related]
23. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
[TBL] [Abstract][Full Text] [Related]
24. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
[TBL] [Abstract][Full Text] [Related]
25. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
Hu X; Karthigeyan KP; Herbek S; Valencia SM; Jenks JA; Webster H; Miller IG; Connors M; Pollara J; Andy C; Gerber LM; Walter EB; Edwards KM; Bernstein DI; Hou J; Koch M; Panther L; Carfi A; Wu K; Permar SR
J Infect Dis; 2024 Feb; ():. PubMed ID: 38324766
[TBL] [Abstract][Full Text] [Related]
26. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans.
Jenks JA; Nelson CS; Roark HK; Goodwin ML; Pass RF; Bernstein DI; Walter EB; Edwards KM; Wang D; Fu TM; An Z; Chan C; Permar SR
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148624
[TBL] [Abstract][Full Text] [Related]
27. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
28. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.
Freed DC; Tang Q; Tang A; Li F; He X; Huang Z; Meng W; Xia L; Finnefrock AC; Durr E; Espeseth AS; Casimiro DR; Zhang N; Shiver JW; Wang D; An Z; Fu TM
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4997-5005. PubMed ID: 24297878
[TBL] [Abstract][Full Text] [Related]
29. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
[TBL] [Abstract][Full Text] [Related]
30. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.
Burke B; Gómez-Román VR; Lian Y; Sun Y; Kan E; Ulmer J; Srivastava IK; Barnett SW
Virology; 2009 Apr; 387(1):147-56. PubMed ID: 19249806
[TBL] [Abstract][Full Text] [Related]
32. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.
Finnefrock AC; Freed DC; Tang A; Li F; He X; Wu C; Nahas D; Wang D; Fu TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2106-2112. PubMed ID: 26986197
[TBL] [Abstract][Full Text] [Related]
34. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
35. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
36. Immunization of Rabbits with Recombinant Human Cytomegalovirus Trimeric versus Monomeric gH/gL Protein Elicits Markedly Higher Titers of Antibody and Neutralization Activity.
Cui X; Cao Z; Wang S; Flora M; Adler SP; McVoy MA; Snapper CM
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261659
[TBL] [Abstract][Full Text] [Related]
37. Vaccines for cytomegalovirus.
Bernstein DI
Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
[TBL] [Abstract][Full Text] [Related]
38. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
[TBL] [Abstract][Full Text] [Related]
39. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.
Marshall GS; Li M; Stout GG; Louthan MV; Duliège AM; Burke RL; Hunt LA
Viral Immunol; 2000; 13(3):329-41. PubMed ID: 11016597
[TBL] [Abstract][Full Text] [Related]
40. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
